Ultragenyx Pharmaceutical Inc. (RARE) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Ultragenyx Pharmaceutical Inc. (RARE) Earnings Overview
As of November 8, 2026, Ultragenyx Pharmaceutical Inc. (RARE) reported trailing twelve-month net income of -$524M, reflecting +7.3% year-over-year growth. The company earned $-5.13 per diluted share over the past four quarters, with a net profit margin of -85.4%.
Looking at the long-term picture, RARE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2011.
Ultragenyx Pharmaceutical Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BMRN (-$19M net income, 10.8% margin), SRPT ($15M net income, -32.5% margin), IONS (-$565M net income, -40.4% margin), RARE has room to improve margins relative to the peer group. Compare RARE vs BMRN →
RARE Earnings vs Peers
Earnings metrics vs comparable public companies
RARE Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$575M | -1.0% | -$535M | $-5.83 | -85.4% | -79.5% |
| 2024 | -$569M | +6.2% | -$536M | $-6.29 | -101.6% | -95.7% |
| 2023 | -$607M | +14.2% | -$569M | $-8.25 | -139.7% | -131.1% |
| 2022 | -$707M | -55.8% | -$649M | $-10.12 | -194.7% | -178.6% |
| 2021 | -$454M | -143.4% | -$382M | $-6.70 | -129.2% | -108.6% |
| 2020 | -$187M | +53.7% | -$330M | $-3.07 | -68.8% | -121.8% |
| 2019 | -$403M | -103.8% | -$424M | $-7.12 | -388.3% | -409.0% |
| 2018 | -$198M | +34.6% | -$371M | $-3.97 | -383.7% | -721.2% |
| 2017 | -$302M | -22.9% | -$329M | $-7.12 | -11567.3% | -12593.5% |
| 2016 | -$246M | -68.8% | -$248M | $-6.21 | -184867.7% | -186471.4% |
| 2015 | -$146M | -143.5% | -$148M | $-3.96 | - | - |
| 2014 | -$60M | -70.5% | -$57M | $-2.08 | - | - |
| 2013 | -$35M | -114.7% | -$32M | $-1.21 | - | - |
| 2012 | -$16M | -138.5% | -$16M | $-0.71 | - | - |
| 2011 | -$7M | - | -$7M | $-0.30 | - | - |
Download Data
Export RARE earnings history in CSV or JSON format
Free sign-in required to download data
RARE Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RARE — Frequently Asked Questions
Quick answers to the most common questions about buying RARE stock.
What is RARE earnings per share (EPS)?
RARE trailing twelve-month (TTM) diluted EPS is $-5.13, reflecting +7.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Ultragenyx Pharmaceutical Inc.'s net income?
Ultragenyx Pharmaceutical Inc. (RARE) trailing twelve-month net income is $-524M as of 2025. Earnings grew +7.3% year-over-year.
Is RARE profitable?
RARE is not currently profitable on a TTM basis, reporting a net loss of $-524M. Net margin is -85.4%. Investors should monitor for a return to profitability.
What is RARE's earnings growth rate?
RARE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are RARE's profit margins?
Ultragenyx Pharmaceutical Inc. net profit margin is -85.4%, operating margin is -79.5%, and gross margin is +83.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -607.5%.
Is RARE growing earnings?
RARE is growing earnings steadily. YoY EPS growth of +7.3% is consistent with the 5-year CAGR of N/A. TTM net income is $-524M.
What was RARE's best earnings year?
Ultragenyx Pharmaceutical Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2011. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were RARE's earnings last quarter?
RARE's most recent reported quarter was Q3 2026. Net income was $-118M with diluted EPS of $-1.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.